As of 2019, approximately 463 million adults ages 20–79 have diabetes worldwide, of which around 90% have T2D1
Up to 40% of patients with type 2 diabetes develop chronic kidney disease2
Patients with stage 3 CKD are 10x more likely to die from any cause (including CV disease) than to progress to stage 5 CKD, dialysis, or kidney transplantation3*
CKD can shorten life expectancy of patients with diabetes by up to 16 years, relative to the general population with neither disease4
*A Norwegian 10-year observational study of patients with CKD stage 3 (N=3047).3
Risk of CV events appears early in the course of CKD in patients with T2D and grows with disease severity.5
CKD progression in T2D follows a path toward declining kidney function, CV decline, and ultimately end-stage renal disease. Once renal function declines below a certain threshold, patients face the complications and risks associated with ESRD.7,8
Despite the standard treatments for ESRD (transplant or dialysis), once patients reach ESRD, approximately 60% will die in the next 5 years. Organ shortages might result in limited transplantation. Even in the best-case scenario, dialysis care or transplantation will result in much less than a naturally functioning kidney, which is why protecting the kidney from CKD progression is of primary importance.7,9,10
CKD: chronic kidney disease; CV: cardiovascular; ESRD: end-stage renal disease; T2D: type 2 diabetes.